{
    "clinical_study": {
        "@rank": "154812", 
        "arm_group": [
            {
                "arm_group_label": "A = PF-06439535", 
                "arm_group_type": "Experimental", 
                "description": "Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1."
            }, 
            {
                "arm_group_label": "B = Bevacizumab-EU", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1."
            }, 
            {
                "arm_group_label": "C = Bevacizumab-US", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to prove that the handling (also referred to as pharmacokinetics) of the\n      following drugs PF-06439535, Avastin\u00ae (bevacizumab) that is licensed for use in the United\n      States (bevacizumab-US) and  Avastin\u00ae (bevacizumab) obtained from Europe (bevacizumab-EU) is\n      similar in healthy male volunteers after receiving a single intravenous dose of either\n      drugs.\n\n      During the course of the study, the similarity in pharmacokinetics will be assessed by\n      sampling the levels of drug in the blood, and by comparing these levels among the different\n      administration arms of PF-06439535, bevacizumab-US and bevacizumab-EU. Safety, tolerability,\n      and immunologic response to the administered drugs will also be evaluated throughout."
        }, 
        "brief_title": "A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects 21-55 years old\n\n          -  Subjects who have previously been exposed to a biologic agent (other than a VEGF\n             [Vascular Endothelial Growth Factor Receptor] inhibitor) may enroll provided that at\n             least 3 months have passed since the last administration of that drug\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50kg (110lbs)\n\n        Exclusion Criteria:\n\n          -  Evidence or history of a clinically significant disease or clinical finding at\n             Screening\n\n          -  Previous treatment with an anti-VEGF antibody, or any other antibody or protein\n             targeting the VEGF receptor."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031991", 
            "org_study_id": "B7391001", 
            "secondary_id": "REFLECTIONS B739-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A = PF-06439535", 
                "description": "Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.", 
                "intervention_name": "PF-06439535", 
                "intervention_type": "Biological", 
                "other_name": "PF-06439535, a potential biosimilar to bevacizumab"
            }, 
            {
                "arm_group_label": "B = Bevacizumab-EU", 
                "description": "Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.", 
                "intervention_name": "Avastin", 
                "intervention_type": "Biological", 
                "other_name": "Bevacizumab (European Union)"
            }, 
            {
                "arm_group_label": "C = Bevacizumab-US", 
                "description": "Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.", 
                "intervention_name": "Avastin", 
                "intervention_type": "Biological", 
                "other_name": "Bevacizumab (United States)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Bioequivalence", 
            "Biosimilarity", 
            "Similarity", 
            "PK", 
            "Phase 1", 
            "Bevacizumab", 
            "Healthy Volunteers", 
            "Single-Dose", 
            "Oncology"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7391001&StudyName=A%20Pharmacokinetic%20Study%20Comparing%20PF-06439535%20And%20Bevacizumab%20In%20Healthy%20Male%20Volunteers%20%28REFLECTIONS%20B739-01%29"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "South Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33143"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031991"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "measure": "Terminal Disposition Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "measure": "Volume of Distribution at Steady State (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 71"
            }, 
            {
                "measure": "Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 - Day 71 or LSLV, whichever occurs later"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}